Cell Therapy and Cell Engineering Facility: Publications

Isabelle Rivière (Core Head)

Cell Therapy and Cell Engineering Facility: Publications

Isabelle Rivière (Core Head)


Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, Maggio A, Sadelain M, Rivière I. Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014 Mar 6;123(10):1483-6. doi: 10.1182/blood-2013-06-507178. Epub 2014 Jan 15.

Sadelain M, Brentjens R, Rivière I. The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discov. 2013 Apr 4. [Epub ahead of print]

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi:10.1126/scitranslmed.3005930. PubMed

Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012 Dec 1;1(9):1577-1583.

Rivière I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood. 2012 Feb 2;119(5):1107-16. Epub 2011 Nov 17.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28. Epub 2011 Aug 17

Mansilla-Soto J, Rivière I, Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. Br J Haematol. 2011 Jun 28.

Papapetrou EP, Lee G, Malani N, Setty M, Rivière I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol. 2010 Dec 12.

Sadelain M, Rivière I, Wang X, Boulad F, Prockop S, Giardina P, Maggio A, Galanello R, Locatelli F, Yannaki E. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann NY Acad Sci. 2010 Aug;1202:52-8.

Brentjens R, Yeh R, Bernal Y, Rivière I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010 Apr;18(4):666-8.

Hasan AN, Selvakumar A, Doubrovina E, Rivière I, Sadelain MW, O’Reilly RJ. Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies. Discov Med. 2009 Dec; 8(43):210-8.

Zhong XS, Matsushita M, Plotkin J, Rivière I, Sadelain M. Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3)kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell-mediated Tumor Eradication. Mol Ther. 2010 Feb;18(2):413-20. Epub 2009 Sep 22.

Ghani K, Wang X, de Campos-Lima P.O, Olszewska M, Kamen A, Rivière I. and M Caruso. Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-pseudotyped Retroviral Vectors Produced in Suspension and Serum-free Media. Hum Gene Ther. 2009. Sep;20(9):966-74.

Sadelain M, Brentjens R and Rivière I. The promise and potential pitfalls of chimeric antigen receptors for cancer therapy. Curr. Opin. Immunol. 2009 Apr;21(2):215-23.

D. Hollyman, J. Stefanski, M. Przybylowski, S. Bartido, O. Borquez-Ojeda, C. Taylor, R.Yeh, V. Capacio, M.Olszewska, J. Hosey, M. Sadelain, R.J. Brentjens and I. Rivière Manufacturing validation of biologically functional T cells targeted to CD19 antigen forautologous adoptive cell therapy. J. Immunother. 32, 169-180 (2009).

Budak-Alpdogan T, Rivière I. Genetic Modification of Human Hematopoietic Cells: Preclinical Optimization of Oncoretroviral-mediated Gene Transfer for Clinical Trials. Methods Mol Biol. 2009;506:33-58.

X. Wang, M. Olszewska, V. Capacio, J. Stefanski, M. Przybylowski, S. Samakoglu, A.H. chang, M. Sadelain and I. Rivière I. Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gammaretrovirus encoded hsvtk suicide genes. Gene Ther. 2008 Nov;15(21):1454-9.

M. Przybylowski, Bartido, S., Borquez-Ojeda, O., Sadelain M. and I. Rivière. Production of clinical grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine. 2007 Jun 28;25(27):5013-24.

J. Yuan, R. Kendle, J. Hodges, G. Heller, M. Sadelain, J. Young and I. Rivière. Scalable expansion of potent genetically modified human Langerhans cells in a closed system for clinical applications . J. Immunotherapy. 2007 Sep;30(6):634-643.

Przybylowski M., Hakakha A., Stefanski J., Hodges J., Sadelain M., and Rivière I. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factorie. Gene Therapy, 2006, 13(1):95-100.